Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ephedrine for Reducing Onset Time of Rocuronium in Elderly Patients
NCT06681662Phase 4Completed
- Start
- Jan 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ephedrine in neuromuscular blockade (NMB) (2 arms). Primary endpoint: Onset time of rocuronium 0.6 mg/kg. Started Jan 2025; status: completed.
02
Drugs
ephedrine
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT06681662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06681662.